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Expression of concentrative nucleoside transporters SLC28
(CNT1, CNT2, and CNT3) along the rat nephron: Effect of
diabetes.
Background. The renal reabsorption of natural nucleosides
and a variety of nucleoside-derived drugs relies on the func-
tion of the apically located, Na+-dependent, concentrative nu-
cleoside transporters CNT1, CNT2, and CNT3 (SLC28A1,
SLC28A2, and SLC28A3). The aims of this study were to de-
termine the segmental localization of the three SLC28 family
members and to establish whether streptozotocin-induced dia-
betes alters their expression.
Methods. SLC28 expression was measured by real-time poly-
merase chain reaction (PCR) on microdissected sections of rat
nephrons. Diabetes was induced by streptozotocin treatment
and the biochemical profiles of control, diabetic, and insulin-
treated rats were established. The effect of diabetes on SLC28
expression was assessed in those segments that significantly ex-
press SLC28 genes.
Results. CNT1-3 mRNAs were expressed in the proximal
tubule and glomerulus. In addition, CNT2 and CNT3 mRNAs
were expressed in the outer medullary and cortical collecting
duct, respectively. Diabetes reduced expression of the three
CNTs in almost all nephron segments, and this effect was not
prevented by an insulin treatment that normalized all blood and
urine parameters. Diabetes increased CNT1 and CNT3 expres-
sion in the glomerulus and insulin treatment decreased it.
Conclusion. The relative distribution of SLC28 gene expres-
sion suggests a role for the proximal tubule in renal nucle-
oside clearance and an accessory role for CNT2 and CNT3,
in adenosine-mediated regulation of collecting duct functions.
Diabetes probably may impair nucleoside clearance indepen-
dently of insulin.
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De novo purine and pyrimidine nucleotide biosynthe-
sis is energetically costly. Thus, mechanisms promoting
nucleoside recycling might contribute to whole-body nu-
cleotide homeostasis. The kidney is likely to play a key
role in this process because nucleoside tubular reabsorp-
tion appears to be highly efficient [1, 2]. In fact, even
though nucleosides are ultrafiltrateable by hemodialy-
sis and, presumably, by the glomerulus, their urinary
clearance is negligible [1, 2]. This feature is probably an
exacerbating factor in inherited diseases of nucleotide
metabolism, such as mitochondrial neurogastrointestinal
encephalomyopathy. In this deficiency in thymidine phos-
phorylase, nucleosides accumulate in the blood, partly
due to their low urinary clearance [1–3], thus lead-
ing to mitochondrial dysfunction. In addition to nat-
ural nucleosides, a variety of drugs currently used in
the treatment of viral diseases and neoplasias are nu-
cleoside derivatives that might also be efficiently reab-
sorbed in kidney tubules. Some of these analogues are
nephrotoxic (for review see [4]). Both natural nucleo-
sides and their pharmacologically active derivatives are
taken up by the same transporters [4–7]. In particular,
CNT carriers (SLC28 gene family) are responsible for
the high-affinity concentrative uptake of natural nucleo-
sides and most of their analogues. CNT1 and CNT2 are
pyrimidine-preferring and purine-preferring carriers re-
spectively, whereas CNT3, the last member of the family
to be cloned, shows a broader substrate selectivity [8].
Although evidence of CNT-related transport activities in
brush border membrane vesicles [9–11] is consistent with
these transporters being expressed in proximal tubules,
the exact localization of the three members of the SLC28
protein family along the nephron is unknown. Thus, the
first goal of this study was to address this particular issue.
CNTs are Na+-coupled transporters. At least for
CNT3, and probably for CNT1, the stoichiometry of
substrate translocation is two Na+ ions per nucleoside
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molecule [8, 12]. Dysregulation of particular sodium-
coupled transporters has been reported in diabetes.
Particularly, increased Na+-glucose cotransport in the
proximal tubule has been associated with tubular growth
and may lead to glomerular hyperfiltration in early di-
abetes [13, 14]. Indeed, increased glomerular filtration
rate (GFR) might be conditioned, or even caused, by al-
tered tubular functions, rather than by primary abnor-
malities of the glomerulus [13, 14]. It should be stressed,
however, that diabetes has opposite effects on different
Na+ transporters. In the proximal tubule, streptozotocin-
induced diabetes increases not only Na+-coupled glu-
cose transport, but also Na+,K+-ATPase activity and sub-
unit mRNA expression [15]. Conversely, proximal tubule
sodium phosphate cotransporter-2 (NaPi-2), sodium hy-
drogen exchanger-3 (NHE3), and thick ascending limb
bumetanide-sensitive Na-K-2 Cl cotransporter (NKCC2)
show decreased protein levels in diabetic Zucker rats
[16]. Thus, the second goal of this study was to deter-
mine whether the expression of the CNTs was altered in
streptozotocin-induced diabetes.
METHODS
Animals
Male Wistar rats (175 to 200 g body weight) (Harlan
Iberica, St. Feliu de Codines, Spain) were kept under
conventional conditions in climate-controlled rooms with
free access to tap water and standard pelleted food ad libi-
tum, on a 12-hour light/dark cycle (light period 8:00 a.m.
to 8:00 p.m.). The following procedures were approved
by the University of Barcelona Ethical Committee on
Animal Experimentation, according to E.U. legislation.
Animals were randomly divided into three groups as fol-
lows: control vehicle-treated rats, streptozotocin-induced
diabetic rats, and diabetic insulin-treated rats. Diabetes
was induced by a single administration of streptozotocin
(65 mg/kg of body weight, intraperitoneally) freshly dis-
solved in citrate buffer, at pH 4.5. Only animals with
blood glucose exceeding 16.6 mmol/L on at least two oc-
casions per week were included in the study. Glucose was
measured with a portable glucose meter (Accutrend
Sensor) (Roche, Mannheim, Germany) on a tail blood
drop. One week after streptozotocin injection, insulin
therapy was started using a human long-acting insulin
preparation (Insulatard NPH) (Novonordisk, Madrid,
Spain). After a subcutaneous priming dose of 10 IU, the
subsequent doses were adjusted according to blood glu-
cose values determined daily at the same time. Insulin
therapy was maintained for 2 weeks. The three groups
of rats were housed together (a total of 3 weeks) until
experiments began.
Biochemical and endocrine profile
Under anesthesia (ketamine 150 mg/kg body weight)
(Imalge`ne, Merial, and xilacin 10 mg/kg body weight)
(Bayer, Rompu´n, Leverkusen, Germany), blood was
sampled from the abdominal aorta into heparinized tubes
and plasma was separated for measurements of glucose,
Na+, K+, urea, and creatinine concentrations. Urine was
obtained by puncture of the urinary bladder for deter-
mination of glucose and albumin. Glucose, urea, creati-
nine, and albumin were measured with a Kodak 700XR
Ektochem Analyzer, and Na+ and K+ concentrations
were determined by flame photometry (Instrumentation
Laboratory, Lexington, MA, USA). The endocrine pro-
file of the animals was established by measuring the
plasma levels of aldosterone (Aldosterone RIA) (Radim,
Rome, Italy) and insulin (CIS Bio International, Gif-sur-
Yvette, France) and the activity of the renin-angiotensin
system (RAS) (RENK P2510) (Sorin Biomedical,
Saluggia, Italy).
Isolation of nephron segments
After anesthesia the left kidney was perfused with
microdissection medium containing 0.24% collagenase
(Serva, Heidelberg, Germany). The microdissection
medium was prepared from Hank’s sterile solution con-
taining 1 g/L glucose and supplemented with 1 mmol/L
lactic acid, 1 mmol/L glutamine, 1 mmol/L sodium pyru-
vate, 0.5 mmol/L MgCl2, 0.1% protease-free serum al-
bumin, and 20 mmol/L Hepes and was adjusted to pH
7.4. Thin pyramids were cut from the kidney, incubated
in 0.15% collagenase solution for 30 minutes at 37◦C,
and then thoroughly rinsed in microdissection solution.
Glomeruli and different nephron segments were mi-
crodissected at 4◦C according to anatomic and morpho-
logic criteria [17]. Several pieces isolated from identical
segments were carefully rinsed to avoid contaminating
cells or debris, and transferred to a denaturing solution
for RNA extraction.
The amplification of excitatory amino acid transporter
3 (EAAT3) mRNA, also called EAAC1, which is a high-
affinity glutamate transporter with a known renal local-
ization [18], was used as a positive control for segment
isolation.
RNA extraction and cDNA synthesis
RNAs were extracted from glomeruli or microdis-
sected segments using a micromethod [19] derived
from the guanidinium thiocyanate-phenol-chloroform
method of Chomczynski and Sacchi [20]. Briefly, pools
of glomeruli or of nephron segments from one individual
animal were transferred with 5 to 10 lL of microdissec-
tion medium into 400 lL of denaturing solution (4 mol/L
guanidinium thiocyanate, 25 mmol/L sodium citrate, pH
7.0, 0.5% sarcosyl, 0.1 mol/L b-mercaptoethanol, and
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20 lg of yeast tRNA) (Sigma Chemical Co., St. Louis, MO,
USA). After phenol-chloroform extraction and isopropyl
alcohol precipitation, the final pellet was vacuum-dried
and resuspended in RNA dilution buffer [10 mmol/L Tris-
HCl, pH 7.6, 1 mmol/L ethylenediaminetetraacetic acid
(EDTA), 2 mmol/L dithiothreitol (DTT), and 40 U/mL
ribonuclease inhibitor (RNasin)] (Promega, Mannheim,
Germany). All RNAs were routinely treated with DNase
I (DNA-Free) (Ambion, Austin, TX, USA), according to
the manufacturer’s instructions. cDNA synthesis was per-
formed from total DNase-treated RNA with 10 lg/mL
random hexamer, 10 mmol/L DTT, 500 lmol/L each
deoxynucleoside triphosphate (dNTPs), and 0.4 U/lL
RNasin, in a final volume of 40 lL. The reaction was
performed for 2 hours at 37◦C.
Real-time quantitative polymerase chain reaction (PCR)
The primers and probes used to amplify nucleoside
transporters rCNT1, rCNT2, glutamate transporter
EAAT3 and glyceraldehyde-3-phosphate-dehydro-
genase (GAPDH) by real-time PCR were designed
using Primer Express Software (Applied Biosystems,
Foster City, CA, USA) are as follows: rCNT1 forward
262-283 (cgactccctcacagtcac), reverse 307-327 (cttccgctct-
gctttgtt), probe 285-303 (ccaccttcaccctccggc); rCNT2
forward 785-803 (ttgcgggaatctgcactgt), reverse 836-854
(ctccagctcaccgcactgt), probe 805-831 (atcctcatcctctttgc
ctgctccaaa); rEAAT3 forward 1223-1244 (cgtgcacaa-
gaggatcacaaga), reverse 1275-1291 (agcgcagtgccgtccat),
probe 1246-1263 (cgccgacgggcagcacaa); and rGAPDH
forward 30-50 (gatggtgaaggtcggtgtcaa), reverse 91-115
(caatgtccactttgtcacaagagaa), probe 70-89 (cgcctggtcccag
ggctgc). In the case of rCNT3, the primers and the probe
were purchased by the Assay-on-Demand Service from
Applied Biosystems.
Real-time monitoring of PCR amplification of cDNAs
was performed using the TaqMan Universal Master Mix
(Applied Biosystems) and 700 nmol/L probe and 150
nmol/L of each primer, in the ABI Prism 7700 Sequence
Detection System (Applied Biosystems). Relative quan-
tification of gene expression and validation of the method
was performed as described in the TaqMan user’s manual
with GAPDH as internal control. Similar amplification
efficiencies for all templates were demonstrated by ana-
lyzing serial cDNA dilutions showing a slope value of log
input cDNA amount versus (CT target A − CT target
B) of < 0.1. The threshold cycle (CT) is defined as the
cycle number at which the fluorescence corresponding to
the amplified PCR product is detected. The CT of
each transporter, expressed as PCR arbitrary units, is de-
fined as the CT of these genes normalized to the GAPDH
level and referred to the expression level in RNA from
total kidney, which is considered level 1. Previous studies
have shown that GAPDH expression is constant through-
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Fig. 1. Distribution of rEAAT3 mRNAs along the rat nephron. (A)
Schematic representation of a renal tubule. (B) Bars represent the
mean ± SE expression of target corresponding to 2 CT (thresh-
old cycle), as described in the Methods section. Abbreviations are:
Glom, glomerulus; PCT, proximal convoluted tubule; PST, proximal
straight tubule; TDL, thin descending limb; CTAL/MTAL, cortical and
medullary portion of the thick ascending limb; CCD/OMCD, cortical
and outer medullary portion of the collecting duct; N.D. Not statistically
different from zero.
out the nephron [21] and unchanged in streptozotocin-
induced diabetes, with or without insulin treatment [22,
23].
RESULTS
Gene expression profile of rCNT1, rCNT2, and rCNT3
along the nephron
The amplification profile of the glutamate transporter
EAAT3 along the nephron was in accordance with the
distribution pattern previously reported by immunolocal-
ization [18], thus confirming an accurate microdissection
of the nephron segments (Fig. 1).
The expression profiles of rCNT1, rCNT2, and rCNT3
mRNAs along the nephron of control rats are shown
in Figure 2. Results confirm the expression of the three
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Table 1. Effects of streptozotocin-induced diabetes and insulin treatment on rat blood composition 3 weeks postinjection
Streptozocin-induced Steptozocin and diabetic
Control diabetes insulin treatment
Na+ mmol/L 142.6 ± 2.3 135.7 ± 1.6a 140.0 ± 1.0
K+ mmol/L 4.84 ± 0.3 4.0 ± 0.3b 4.1 ± 0.2
Glucose mmol/L 4.4 ± 0.2 27.3 ± 1.4a 2.6 ± 0.7
Creatinine lmol/L 40.2 ± 2.0 50.2 ± 2.7a 33.8 ± 1.9
Urea mmol/L 4.9 ± 0.1 8.5 ± 1a 3.8 ± 0.4
Insulin ng/mL 36.6 ± 6.9 4.7 ± 0.7a 19.1 ± 5.0
Renin-angiotensin system ng/mL/hour 12.8 ± 2.3 25.3 ± 1.0a 15.3 ± 3.8
Aldosterone nmol/L 0.9 ± 0.1 2.2 ± 0.3a 0.8 ± 0.1
Values are ± SE of measurements made on 7 to 12 animals.
aP < 0.01; bP < 0.05, values significantly different from control using analysis of variance (ANOVA) and the Dunnett post test.
CNT family members in the proximal convoluted and
straight tubule, with abundance two- to fourfold higher
in proximal convoluted tubules than in proximal straight
tubles. Unexpectedly, they also demonstrate expression
of the three CNTs in the glomerulus which, in case of
CNT2 is > threefold higher than in proximal convolutes
tubule. Finally, they reveal high expression levels of CNT2
and CNT3 mRNAs in the outer medullary and cortical
collecting duct, respectively. In other nephron segments,
CNT1-3 mRNAs were amplified at the limit of detection
for this technique. Moreover, this was feasible in some
but not all animals, thus resulting in a mean value that is
not statistically different from zero.
Biochemical and endocrine profiles in
streptozotocin-induced diabetes
One week after streptozotocin injection, rats exhibited
overt hyperglycemia with blood glucose levels above 20
mmol/L. At the end of the study, streptozotocin-treated
animals had blood glucose concentration nearly seven-
fold higher than that of control and insulin-treated ani-
mals, accompanied with a sevenfold decrease in plasma
insulin (Table 1). This impaired glucoregulation, a charac-
teristic feature of untreated diabetes, resulted in growth
deficiency. Under pair-feeding conditions, body weight of
control and insulin-treated rats increased by >40% dur-
ing the 3-week study, whereas that of diabetic animals
increased by only 10%. Moreover, the kidney weight and
kidney/body weight ratio were significantly increased in
diabetic rats compared with control and insulin-treated
animals (Table 2), demonstrating renal hypertrophy.
This renal hypertrophy characterizes the early stage
of diabetic nephropathy and is often accompanied with
altered renal function. Indeed, 3 weeks after streptozo-
tocin injection, plasma creatinine and urea concentra-
tions were higher in diabetic than in control rats. The
RAS activity and aldosterone concentration were also
higher (Table 1). Furthermore, diabetic animals showed
a significant increase in the urine levels of glucose and
albumin, the latter being consistent with the presence of
early microalbuminuria (Fig. 3). Insulin treatment com-
Table 2. Effects of streptozotocin-induced diabetes and insulin
treatment on rat body and kidney weight 3 weeks postinjection
Body Kidney Kidney/body
weight g weight g weight (×1000)
Control 253 ± 12 1.06 ± 0.02 4.2
Streptozocin-induced 204 ± 6a 1.33 ± 0.03a 6.5
diabetes
Streptozotin and diabetic 269 ± 6 1.04 ± 0.03 3.9
insulin treatment
Values are ±SE of measurements made on 7 to 12 animals per experimental
group.
aP < 0.0l, values significantly different from control using analyis of variance
(ANOVA) and the Dunnett post test.
pletely prevented all these alterations, consistent with rats
being at the early stage of diabetic nephropathy.
Effect of diabetes on rCNT1, rCNT2, and rCNT3
expression
The effects of streptozotocin-induced diabetes and in-
sulin treatment on CNTs expression are summarized in
Figure 4. All results were normalized to the expression
level in the different kidney structures of normal rats.
In proximal tubules (proximal convoluted tubules and
proximal straight tubules), expression of all three CNT
mRNAs was reduced in diabetic rats (although the de-
crease was not significant for CNT1 in proximal straight
tubules). CNT3 expression was fully abolished during di-
abetes in all segments of the nephron; this effect was not
reversed by insulin therapy. The same patterns were ob-
served for CNT2 and CNT3 expression in outer medullar
collecting duct and cortical collecting duct, respectively.
In contrast, diabetes was associated with increased ex-
pression of CNT1 and CNT3, but not CNT2, mRNAs in
the glomerulus. Insulin not only prevented the induction
of CNT1 and CNT3 expression observed in the glomeru-
lus of diabetic rats, but reduced it well below control level.
DISCUSSION
This study provides novel insights into the physiol-
ogy of three renal transporters that are involved in the
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Fig. 2. Distribution profile of concentrative nucleoside transporter
(CNT) mRNAs along the rat nephron. Quantitative real-time reverse
transcription-polymerase chain reaction (RT-PCR) analysis of rCNT1
(A), rCNT2 (B) and rCNT3 (C) mRNAs in the glomerulus and differ-
ent segments of the rat renal tubule. Values are ±SE of measurements
made on at least four animals. PCR arbitrary units were obtained as de-
scribed in the Methods section. Abbreviations are: Glom, glomerulus;
PCT, proximal convoluted tubule; PST, proximal straight tubule; TDL,
thin descending limb; CTAL/MTAL, cortical and medullary portion of
the thick ascending limb; CCD/OMCD, cortical and outer medullary
portion of the collecting duct; N.D. Not statistically different from zero.
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Fig. 3. Effects of 3 weeks streptozotocin-induced diabetes (STZ) and
insulin treatment (STZ + INS) on urine composition. Values are ±SE
of measurements made on at least four animals. ∗∗P < 0.01, values
significantly different from control using analysis of variance (ANOVA)
and the Dunnett post test.
reabsorption of natural nucleosides, as well as nucleoside-
derived drugs used in anticancer and antiviral therapies.
This view is supported by recent evidence that the het-
erologous expression of CNT1 to CNT3 in epithelial cells
results in their apical insertion [24–26], confirming previ-
ous findings that CNT1 and CNT2 transport activities are
present in renal brush border membrane vesicles [9–11].
In contrast, the equilibrative nucleoside transporters are
located at the basolateral pole of the cells [25]. Expression
of CNTs and equilibrative nucleoside transporters at the
apical and basolateral poles of renal cells, respectively,
would be consistent with vectorial reabsorption of nu-
cleosides and their derivatives. The putative role of CNT
transporter proteins in tubular nucleoside reabsorption is
further supported by their high relative abundance in the
proximal tubule (proximal convoluted tubule and proxi-
mal straight tubule) reported here.
Besides this putative role in nucleoside and nucleoside-
derived drug clearance, the possibility that these
transporter proteins contribute to nucleoside salvage to
fulfill nucleotide requirements for biosynthetic purposes,
along with the possibility that high-affinity nucleoside
transporters play other physiologic roles beyond salvage,
might help to explain why CNT1, CNT2, and CNT3 dis-
tribution patterns along the nephron and glomerulus do
not completely coincide.
One possible explanation for the different distribution
pattern of these three transporters, particularly the rela-
tively high abundance of CNT2 in the glomerulus and
outer medullary collecting duct and of CNT3 in cor-
tical collecting duct, is that CNT2 and CNT3 are effi-
cient adenosine transporters, whereas CNT1 is not [27].
Adenosine is a modulator of tubuloglomerular feedback
[28] and is believed to be a paracrine factor in the con-
trol of glomerular function [29]. Adenosine can also
inhibit Na+ reabsorption across the collecting duct, a
segment that is particularly rich in adenosine receptors
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Fig. 4. Effect of diabetes and insulin treatment on renal concentrative
nucleoside transporter rCNT1 (A), rCTN2 (B), and CTN3 (C) mRNA
distribution in the rat nephron. Values were standardized to control
group for each nephron segment. Bars represent ±SE of measurements
made on at least four animals. ∗∗P < 0.01, values significantly different
from control using analysis of variance (ANOVA) and the Dunnett post
test. Abbreviations are: Glom, glomerulus; PCT, proximal convoluted
tubule; PST, proximal straight tubule; CCD, cortical collecting duct;
STZ, streptozocin-induced diabetes; STZ + INS, streptozotocin and
insulin-induced diabetes.
[30]. Indeed, as for CNT2 and CNT3, A1-adenosine re-
ceptor (A1R) mRNA is differentially expressed within
the nephron [31], with strong expression in the collect-
ing duct. Interestingly, A2A-adenosine receptor (A2A)
mRNA, which is absent along the nephron, is exclusively
localized in the glomerulus [31], where high expression of
adenosine transporters has also been found. Moreover,
as for CNT2 [24], the heterologous expression of A1R
in renal epithelial cells results in the insertion of this
receptor into both apical and basolateral domains [32].
The occurrence of adenosine receptors and high-affinity
transporters on the apical side of epithelial cells in distal
segments of the nephron would be consistent with effi-
cient adenosine biosynthesis in the collecting duct, origi-
nated mostly from extracellular tubular cyclic adenosine
monophosphate (cAMP), a phenomenon called the “ex-
tracellular cAMP adenosine pathway” [33]. CNT2 and
CNT3 are indeed suitable candidates to regulate the ac-
cessibility of extracellular adenosine to adenosine recep-
tors, although no evidence for this functional relationship
has been provided in renal cells. Nevertheless, it has been
recently shown that CNT2 activity is under purinergic
control via KATP channels in rat hepatocytes [34]. CNT2
protein is highly abundant at the basolateral membranes
of hepatocytes [35], where it colocalizes with A1R [34].
Whether this type of regulation occurs in epithelial renal
cells is currently under investigation.
Nevertheless, as discussed above, what is common to
all SLC28 transporters is their high mRNA expression in
the proximal tubule. This would favor the view that, as
for many other metabolites, such as glucose and amino
acids [36, 37], this segment is particularly implicated in
tubular reabsorption of nucleosides, and thus the greatest
contributor to their renal clearance.
Diabetes modifies the expression of selected Na+-
coupled transporters in the kidney. Here it is shown
that streptozotocin-induced diabetes in the rat causes a
dramatic decrease in CNT1, CNT2, and CNT3 mRNA
amounts in segments that are likely to contribute to nucle-
oside reabsorption (principally the proximal convoluted
tubule). Diabetes also dramatically decreases CNT2 and
CNT3 mRNA in proximal convoluted tubule and distal
segments. It is likely that changes in mRNA levels result
in concomitant variations in both protein amounts and
transport function, since in a variety of cell models cur-
rently used in our laboratory, changes in mRNA amounts
are followed by similar variations in CNT-related trans-
port activities [38–41]. The fact that diabetes does not
significantly decrease CNT mRNA levels in glomerulus
would be consistent with a housekeeping role of these
transporters for nucleoside salvage, whereas the major
route for renal nucleoside clearance might be altered
in diabetes. Nevertheless, CNT1 mRNA levels do in-
crease in glomerulus of diabetic rats. Interestingly, this
phenomenon would be consistent with previous findings
showing that early renal hypertrophy in streptozotocin-
induced diabetes is associated with increased pyrimidine
nucleotide synthesis and salvage in whole kidney [42],
whereas the biosynthesis of uracil nucleotides and deriva-
tives in the glomerulus is significantly increased [43].
Another finding of this study is the inability of in-
sulin treatment, started 1 week after streptozotocin
injection, to restore CNT expression in the proximal con-
voluted tubule, as determined 3 weeks after induction
of diabetes. This is particularly relevant because all bio-
chemical and endocrine parameters evaluated here were
completely normalized when appropriate glucoregula-
tion was achieved. Since the hyperaldosteronism and the
high activity of the RAS were appropriately reversed by
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insulin, we conclude that these hormones do not play a
significant role in regulating CNT expression in the kid-
ney. Moreover, the persistence of these alterations in the
proximal convoluted tubule after insulin treatment, when
all biochemical parameters have been restored, suggests
that loss of CNT1, CNT2, and CNT3 function may be a
relatively early, irreversible event in the development of
diabetic nephropathy.
CONCLUSION
This study describes, for the first time, the segmental
distribution of the three concentrative nucleoside trans-
porters of the SLC28 gene family (CNT1, CNT2, and
CNT3) in the rat kidney. Their relative distribution sug-
gests a role for the proximal convoluted tubule in re-
nal nucleoside clearance and an accessory role for CNT2
and perhaps for CNT3, in adenosine-mediated regulation
of renal function. Diabetes is associated with a dramatic
decrease in CNT1, CNT2, and CNT3 mRNA levels in
the proximal convoluted tubule, proximal straight tubule,
and selected distal segments, which is likely to impair nu-
cleoside clearance.
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